<p>想要通過投資一些炫酷的股票來豐富你的投資組合嗎？考慮一下目前被低估的大麻股票。大麻股票讓投資者有機會投資一些具有顛覆性和革命性的東西。</p>
<p>儘管目前在美國 24 個州已經完全合法化，但大麻在聯邦層面仍受限制。今年，司法部動議將大麻重新分類為一種較不危險的藥物。這聽起來可能是一個小決定，但事實上，鑑於幾十年來合法化大麻所遭遇的阻力，這是具有歷史意義的。</p>
<p>儘管這一步驟很重要，但仍遠遠沒有讓大麻在聯邦層面獲得批准。但對於熱愛大麻的人和企業來説，這對話題解禁大麻注入了新的活力，這對該領域的公司和投資者都是一個好兆頭。以下是本月值得購買的三家最被低估的大麻股票。</p>
<p>此外，這也為解禁大麻的討論注入了新的活力，這對該領域的公司和投資者都是一個好兆頭。以下是本月值得購買的三家最被低估的大麻股票。</p>
<h2>綠拇指產業（GTBIF）</h2>
<p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>來源：Wirestock Creators / Shutterstock.com</p>
<p><strong>綠拇指產業</strong>（OTCMKTS:<strong>GTBIF</strong>）股價整個 2024 年都在橫盤交易，但這並不會明顯抑制投資者情緒。</p>
<p>從樂觀的分析師評級（14 個買入對一個超重建議）到上一季度強勁的財務狀況，綠拇指產業的短期和長期前景看起來非常有前途，目前是最被低估的大麻股票之一。</p>
<p>這家總部位於芝加哥的公司上一季度實現了 2.76 億美元的營收，較上一年增長了 11.0%。零售收入特別是相比 2023 年第一季度增長了 7.9%。</p>
<p>綠拇指表示，這一增長得益於在 15 家新開業的 RISE 藥店和馬里蘭州成人用藥銷售的增加。</p>
<p>其健康的財務狀況的其他指標包括調整後的 EBITDA 為 9100 萬美元，佔營收的 33% — 比上一年增長了 19%，現金流較 2023 年第一季度增長了 12%。</p>
<h2>Trulieve（TCNNF）</h2>
<p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>來源：Leigh Trail / Shutterstock.com</p>
<p><strong>Trulieve</strong>（OTCMKTS:<strong>TCNNF</strong>）是一家垂直整合（意味着它控制其供應鏈的所有階段）的美國大麻公司。其品牌組合包括較小的高端品牌，如 Avenue、Cultivar Collection 和 Muse。其他品牌包括中檔品牌 Modern Flower、Alchemy、Momenta 和 Sweet Talk，以及價值品牌 Co2lors、Loveli、Roll One 和 Trekkers。</p>
<p>根據其最近的市場表現和基本面，Trulieve 目前是最有前景的被低估的大麻股票之一。目前的股價為 9.90 美元，股價比年初上漲了近 90%，當時股價約為 5 美元。</p>
<p>Trulieve 在財務方面也表現不錯。上一季度，其營收同比增長了 4%，並計劃擴張到佛羅里達州的科科海灘、棕櫚灣和皮內拉斯公園的三家藥店，這將增加其底線。</p>
<p>令人興奮的是，分析師們普遍推薦 Trulieve 股票，這進一步説明了它們升值潛力。</p>
<h2>Tilray Brands（TLRY）</h2>
<p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>來源：rafapress / Shutterstock.com</p>
<p><strong>Tilray Brands</strong>（NASDAQ:<strong>TLRY</strong>）在包括加拿大、美國、歐洲、澳大利亞、新西蘭和拉丁美洲在內的幾個大陸種植、加工和分銷醫用大麻產品。</p>
<p>該公司最初是一家純粹以大麻為重點的企業，但現在已將自己打造成一個綜合性的生活方式公司。它現在在四個領域運營：大麻、基於大麻的食品、飲料酒精和健康。</p>
<p>該公司的多樣化以及一系列收購是對大麻業務的經濟現實做出的務實回應。由於產品受到聯邦限制，真正的盈利仍然難以實現。</p>
<p>這種多樣化幫助其保持盈利，並且甚至實現了令人印象深刻的營收。例如，截至 2 月 29 日的季度，Tilray 的營收為 1.883 億美元，同比增長了 30%。</p>
<p>此外，該公司計劃在未來幾個月和年份內達成更多交易。首席執行官歐文·西蒙告訴 MarketWatch，他將在 2024 年繼續尋求 “進行更多收購”。</p>
<p>投資者還將高興地得知，華爾街分析師看好 Tilray 的上漲潛力。股票的平均評級為持有，有三個買入建議，12 個持有評級，沒有低於持有或賣出評級。</p>
<p>Tilray 目前是最佳的被低估的大麻股票之一。</p>
<p><em>在發佈日期，Hope Mutie 在本文提到的股票中沒有（直接或間接）任何持倉。本文中表達的觀點屬於作者本人，受到 InvestorPlace.com 的</em> <em>發佈指南</em> _的約束。</p>
<p><em>在發佈日期，負責編輯在本文提到的證券中沒有（直接或間接）任何持倉。</em></p>
<p>Hope Mutie 是一位對金融和加密貨幣充滿熱情的作家。在 InvestorPlace，她緊跟股票和加密市場的脈搏，創作富有見地和信息豐富的內容，幫助投資者以信心駕馭市場。</p>
<p>被低估的股票</p>

TLRY

<p>2024 年 7 月最被低估的三家大麻股票是 Green Thumb Industries (GTBIF)、Trulieve (TCNNF) 和 Tilray Brands (TLRY)。Green Thumb Industries 擁有強勁的財務狀況和前景，而 Trulieve 則在市場表現和分析師推薦方面表現顯著。Tilray Brands 已經多元化其業務，併發布了令人印象深刻的收入數據。這些股票為投資者提供了在顛覆性和革命性大麻行業中的投資機會</p>

<p>Looking to round out your portfolio with cool stock options? Consider these currently undervalued cannabis stocks. Cannabis stocks give investors the chance to invest in something disruptive and revolutionary.</p>
<div class="lb-trans"><p>想要通過投資一些炫酷的股票來豐富你的投資組合嗎？考慮一下目前被低估的大麻股票。大麻股票讓投資者有機會投資一些具有顛覆性和革命性的東西。</p>
</div><p>And though it’s now fully legal in 24 U.S. states, cannabis is still restricted at the federal level. The Justice Department moved to reclassify cannabis as a less dangerous drug this year. That might sound like a small decision, but it is, in fact, historic, given the pushback efforts to legalize cannabis have encountered over the decades.</p>
<div class="lb-trans"><p>儘管目前在美國 24 個州已經完全合法化，但大麻在聯邦層面仍受限制。今年，司法部動議將大麻重新分類為一種較不危險的藥物。這聽起來可能是一個小決定，但事實上，鑑於幾十年來合法化大麻所遭遇的阻力，這是具有歷史意義的。</p>
</div><p>Though significant, that step still doesn’t come close to having marijuana federally approved. But it moves the needle big-time for cannabis lovers and businesses.</p>
<div class="lb-trans"><p>儘管這一步驟很重要，但仍遠遠沒有讓大麻在聯邦層面獲得批准。但對於熱愛大麻的人和企業來説，這對話題解禁大麻注入了新的活力，這對該領域的公司和投資者都是一個好兆頭。以下是本月值得購買的三家最被低估的大麻股票。</p>
</div><p>Also, it injects fresh energy into the conversation on decriminalizing marijuana, which bodes well for companies and investors in the niche. Here are the three most undervalued cannabis stocks to buy this July.</p>
<div class="lb-trans"><p>此外，這也為解禁大麻的討論注入了新的活力，這對該領域的公司和投資者都是一個好兆頭。以下是本月值得購買的三家最被低估的大麻股票。</p>
</div><h2>Green Thumb Industries (GTBIF)</h2>
<div class="lb-trans"><h2>綠拇指產業（GTBIF）</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif" alt="" original-src="https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>Source: Wirestock Creators / Shutterstock.com</p>
<div class="lb-trans"><p>來源：Wirestock Creators / Shutterstock.com</p>
</div><p><strong>Green Thumb Industries</strong> (OTCMKTS:<strong>GTBIF</strong>) shares have been trading sideways the whole of 2024, but that shouldn’t so nearly dampen investor sentiment.</p>
<div class="lb-trans"><p><strong>綠拇指產業</strong>（OTCMKTS:<strong>GTBIF</strong>）股價整個 2024 年都在橫盤交易，但這並不會明顯抑制投資者情緒。</p>
</div><p>From glowing analyst ratings (14 Buy against one Overweight recommendation) to strong financials for the last quarter, Green Thumb Industries’ short-term and long-term prospects look ultra promising, and it’s one the most undervalued cannabis stocks at the moment.</p>
<div class="lb-trans"><p>從樂觀的分析師評級（14 個買入對一個超重建議）到上一季度強勁的財務狀況，綠拇指產業的短期和長期前景看起來非常有前途，目前是最被低估的大麻股票之一。</p>
</div><p>The Chicago-headquartered firm posted revenues of $276 million for its last quarter, an 11.0% increase from the previous year. Retail revenue specifically saw a 7.9% rise compared to Q1 2023.</p>
<div class="lb-trans"><p>這家總部位於芝加哥的公司上一季度實現了 2.76 億美元的營收，較上一年增長了 11.0%。零售收入特別是相比 2023 年第一季度增長了 7.9%。</p>
</div><p>Green Thumb said this growth was fueled by higher sales in retail and consumer packaged goods across 15 newly opened RISE Dispensaries and the introduction of adult-use sales in Maryland.</p>
<div class="lb-trans"><p>綠拇指表示，這一增長得益於在 15 家新開業的 RISE 藥店和馬里蘭州成人用藥銷售的增加。</p>
</div><p>Other indications of its healthy financial status include adjusted EBITDA of $91 million or 33% of revenue — a 19% bump from the previous year and a 12% increase in cash flow compared to Q1 of 2023.</p>
<div class="lb-trans"><p>其健康的財務狀況的其他指標包括調整後的 EBITDA 為 9100 萬美元，佔營收的 33% — 比上一年增長了 19%，現金流較 2023 年第一季度增長了 12%。</p>
</div><h2>Trulieve (TCNNF)</h2>
<div class="lb-trans"><h2>Trulieve（TCNNF）</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif" alt="" original-src="https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>Source: Leigh Trail / Shutterstock.com</p>
<div class="lb-trans"><p>來源：Leigh Trail / Shutterstock.com</p>
</div><p><strong>Trulieve</strong> (OTCMKTS:<strong>TCNNF</strong>) is a vertically integrated (meaning it controls all the stages of its supply chain) U.S. cannabis company. It has a brand portfolio that includes smaller premium brands such as Avenue, Cultivar Collection and Muse. Others include mid-tier brands Modern Flower, Alchemy, Momenta and Sweet Talk, and value brands Co2lors, Loveli, Roll One and Trekkers.</p>
<div class="lb-trans"><p><strong>Trulieve</strong>（OTCMKTS:<strong>TCNNF</strong>）是一家垂直整合（意味着它控制其供應鏈的所有階段）的美國大麻公司。其品牌組合包括較小的高端品牌，如 Avenue、Cultivar Collection 和 Muse。其他品牌包括中檔品牌 Modern Flower、Alchemy、Momenta 和 Sweet Talk，以及價值品牌 Co2lors、Loveli、Roll One 和 Trekkers。</p>
</div><p>Going by its recent market performance and fundamentals, Trulieve is one of the most promising undervalued cannabis stocks right now. At the current going price of $9.90, shares are up nearly 90% from the turn of the year when they traded at the ballpark of $5 apiece.</p>
<div class="lb-trans"><p>根據其最近的市場表現和基本面，Trulieve 目前是最有前景的被低估的大麻股票之一。目前的股價為 9.90 美元，股價比年初上漲了近 90%，當時股價約為 5 美元。</p>
</div><p>Trulieve is not doing too shabby either on the financial front. It recorded a 4% sequential increase of 4% year-on-year (YOY) in revenue for the last quarter. And its planned expansion into three more dispensaries at Cocoa Beach, Palm Bay and Pinellas Park, Florida, will add to its bottom line.</p>
<div class="lb-trans"><p>Trulieve 在財務方面也表現不錯。上一季度，其營收同比增長了 4%，並計劃擴張到佛羅里達州的科科海灘、棕櫚灣和皮內拉斯公園的三家藥店，這將增加其底線。</p>
</div><p>It’s also exciting to note analysts overwhelmingly recommend Trulieve shares, which should further illustrate their potential to soar in value.</p>
<div class="lb-trans"><p>令人興奮的是，分析師們普遍推薦 Trulieve 股票，這進一步説明了它們升值潛力。</p>
</div><h2>Tilray Brands (TLRY)</h2>
<div class="lb-trans"><h2>Tilray Brands（TLRY）</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif" alt="" original-src="https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>Source: rafapress / Shutterstock.com</p>
<div class="lb-trans"><p>來源：rafapress / Shutterstock.com</p>
</div><p><strong>Tilray</strong> <strong>Brands</strong>(NASDAQ:<strong>TLRY</strong>) cultivates, processes and distributes medical cannabis products across several continents including Canada, the United States, Europe, Australia, New Zealand and Latin America.</p>
<div class="lb-trans"><p><strong>Tilray Brands</strong>（NASDAQ:<strong>TLRY</strong>）在包括加拿大、美國、歐洲、澳大利亞、新西蘭和拉丁美洲在內的幾個大陸種植、加工和分銷醫用大麻產品。</p>
</div><p>The company began as a purely cannabis-focused business but has since fashioned itself as an overall lifestyle company. It now operates across four segments: cannabis, hemp-based foods, beverage alcohol and wellness.</p>
<div class="lb-trans"><p>該公司最初是一家純粹以大麻為重點的企業，但現在已將自己打造成一個綜合性的生活方式公司。它現在在四個領域運營：大麻、基於大麻的食品、飲料酒精和健康。</p>
</div><p>The company’s diversification plus a raft of acquisitions is a pragmatic response to the economic realities of the cannabis business. Real profitability remains elusive — thanks to the federal restrictions on the product.</p>
<div class="lb-trans"><p>該公司的多樣化以及一系列收購是對大麻業務的經濟現實做出的務實回應。由於產品受到聯邦限制，真正的盈利仍然難以實現。</p>
</div><p>That diversification has helped it stay afloat and even post impressive revenues. For example, Tilray’s revenue for the quarter ending February 29 was $188.3 million, which was a 30% jump YOY.</p>
<div class="lb-trans"><p>這種多樣化幫助其保持盈利，並且甚至實現了令人印象深刻的營收。例如，截至 2 月 29 日的季度，Tilray 的營收為 1.883 億美元，同比增長了 30%。</p>
</div><p>Furthermore, the company plans to seal more deals in the coming months and years. CEO Irwin Simon told MarketWatch he’d be looking to “do more acquisitions in 2024.”</p>
<div class="lb-trans"><p>此外，該公司計劃在未來幾個月和年份內達成更多交易。首席執行官歐文·西蒙告訴 MarketWatch，他將在 2024 年繼續尋求 “進行更多收購”。</p>
</div><p>Investors will also be enthused to know Wall Street analysts see an upside potential in Tilray. Shares have an average rating of Hold, with three Buy recommendations, 12 Hold ratings and no Underweight or Sell ratings.</p>
<div class="lb-trans"><p>投資者還將高興地得知，華爾街分析師看好 Tilray 的上漲潛力。股票的平均評級為持有，有三個買入建議，12 個持有評級，沒有低於持有或賣出評級。</p>
</div><p>Tilray is one of the best-undervalued cannabis stocks at the moment.</p>
<div class="lb-trans"><p>Tilray 目前是最佳的被低估的大麻股票之一。</p>
</div><p><em>On the date of publication, Hope Mutie did not have (either directly or indirectly) any positions in the stocks mentioned in this article. The opinions expressed in this article are those of the writer, subject to InvestorPlace.com’s</em> <em>Publishing Guidelines.</em></p>
<div class="lb-trans"><p><em>在發佈日期，Hope Mutie 在本文提到的股票中沒有（直接或間接）任何持倉。本文中表達的觀點屬於作者本人，受到 InvestorPlace.com 的</em> <em>發佈指南</em> _的約束。</p>
</div><p><em>On the date of publication, the responsible editor did not have (either directly or indirectly) any positions in the securities mentioned in this article.</em></p>
<div class="lb-trans"><p><em>在發佈日期，負責編輯在本文提到的證券中沒有（直接或間接）任何持倉。</em></p>
</div><p>Hope Mutie is a writer who’s enthusiastic about finance and crypto. At InvestorPlace, she keeps her finger on the pulse of the stock and crypto markets to create insightful and info-rich content to help investors navigate the market with confidence.</p>
<div class="lb-trans"><p>Hope Mutie 是一位對金融和加密貨幣充滿熱情的作家。在 InvestorPlace，她緊跟股票和加密市場的脈搏，創作富有見地和信息豐富的內容，幫助投資者以信心駕馭市場。</p>
</div><p>Undervalued Stocks</p>
<div class="lb-trans"><p>被低估的股票</p>
</div>

2024 年 7 月最值得購買的三隻被低估的大麻股票